Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820556 | 1.00 | CTSL (0.37) | CTSLCACNA1BMEN1KMT2AMCL1 | |
| SCHEMBL818270 | 0.84 | DPP8 (0.37) | MEN1KMT2AMCL1 | |
| SCHEMBL820554 | 0.83 | MCL1 (0.35) | MEN1KMT2AMCL1 | |
| SCHEMBL818582 | 0.83 | MCL1 (0.35) | MEN1KMT2AMCL1 | |
| SCHEMBL13787013 | 0.82 | AAK1 (0.33) | CTSLCACNA1BAAK1 | |
| SCHEMBL817543 | 0.80 | CAPN1 (0.35) | CTSL | |
| SCHEMBL15501147 | 0.70 | BIRC3 (0.39) | — | |
| SCHEMBL12405720 | 0.70 | BIRC3 (0.39) | — | |
| SCHEMBL820709 | 0.70 | KDM4E (0.39) | MEN1KMT2A | |
| SCHEMBL12474013 | 0.68 | BIRC3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2242362-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | CTSL 604/4885CACNA1B 3395/4885MEN1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.